前列地尔注射液联合厄贝沙坦治疗糖尿病肾病的临床观察

摘要

目的：比较观察前列地尔注射液联合厄贝沙坦与单用厄贝沙坦治疗糖尿病肾病的疗效。方法将56例糖尿病肾病患者随机分为治疗组和对照组，治疗组给予前列地尔注射液联合厄贝沙坦治疗，对照组单用厄贝沙坦治疗，疗程为4w，观察两组治疗前后血肌酐、尿素氮、24h尿微量白蛋白的变化。结果治疗组和对照组治疗前血肌酐、尿素氮、24h尿微量白蛋白差异无统计学意义（P>0.05）；治疗后治疗组较对照组的血肌酐、尿素氮、24h尿微量白蛋白改善明显，两组间差异具有统计学意义(P<0.05)。结论前列地尔注射液联合厄贝沙坦治疗糖尿病肾病有比较好的安全性和耐受性，能有效的降低尿蛋白含量，是一种有效治疗糖尿病肾病的方法。%Objective compare the curative ef ect of diabetic nephropathy between alprostadil joint irbesartan and lonely irbesartan. Methods:56 cases of diabetic nephropathy patients were randomly divided into treatment group and control group, Treatment group given alprostadil joint irbesartan treatment;Observe two groups before and after treatment serum creatinine, blood urea nitrogen, the change of the 24 h urine trace albumin. Result:Treatment group than the control group after treatment, the serum creatinine, blood urea nitrogen, 24 h urine trace albumin improves obviously, statistical y significant dif erence between the two groups (P<0.05). Conclusion:alprostadil joint irbesartan treatment of diabetic nephropathy have bet er safety and tolerability, can ef ectively reduce the urine protein, is an ef ective method for the treatment of diabetic nephropathy.